Curevac and gsk enter into pandemic preparedness contract with german government

- german government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mrna vaccines developed by curevac and gsk - five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency, contributing to increased pandemic preparedness tÜbingen, germany and boston, ma / accesswire / april 11, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), and gsk today announced that they have entered into a contract with the german federal government to supply mrna vaccines within a broader tender for pandemic preparedness in germany.
CVAC Ratings Summary
CVAC Quant Ranking